Short-Term Outcomes of Magnetically Levitated Left Ventricular Assist Device in Advanced Heart Failure ― The Japanese Cohort ―
-
- Inoue Koichi
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Fujita Tomoyuki
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Yoshioka Daisuke
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Tonai Kohei
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Yanagino Yusuke
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Kakuta Takashi
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Tadokoro Naoki
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Kawamoto Naonori
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Yamashita Kizuku
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Kawamura Ai
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Matsuura Ryohei
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Kawamura Takuji
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Saito Tetsuya
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Kawamura Masashi
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Kainuma Satoshi
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Fukushima Satsuki
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center
-
- Toda Koichi
- Department of Cardiovascular Surgery, Osaka University Hospital
-
- Miyagawa Shigeru
- Department of Cardiovascular Surgery, Osaka University Hospital
この論文をさがす
抄録
<p>Background: The superiority of a fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) in terms of overall survival, stroke events and pump thrombosis has been demonstrated in previous international analyses, so we evaluated a Japanese cohort for the same.</p><p>Methods and Results: This retrospective observational study was conducted at Osaka University Medical Hospital and the National Cerebral and Cardiovascular Center in Japan. A total of 75 consecutive patients who underwent HeartMate3 (HM3) implantation were included. The primary endpoint was on-device survival, and the secondary endpoint was the incidence of LVAD-related complications at 2 years. All parameters were compared with those of the previously performed HeartMate II (HMII) implantation in 197 cases. The on-device survival rates were 94.7% and 92.3% in the HM3 and HMII groups, respectively, at the 2-year follow-up (P=0.62). The rehospitalization-free rate after implantation was 61.8% in the HM3 group, which was significantly higher than that in the HMII group (relative risk, 0.35; 95% confidence interval [CI], 0.23–0.55; P<0.0001). Event-free survival rates from cerebral cerebrovascular events and pump thrombosis in the HM3 group were significantly higher than those in the HMII group, at 97.2% and 100%, respectively (relative risk, 0.14; 95% CI 0.03–0.58); P=0.0015 and relative risk, not calculated; P=0.049, respectively).</p><p>Conclusions: Satisfactory short-term outcomes were observed after HM3 implantation in a Japanese cohort.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 86 (12), 1961-1967, 2022-11-25
一般社団法人 日本循環器学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390857158422029184
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 032526123
-
- PubMed
- 36273915
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
-
- 抄録ライセンスフラグ
- 使用不可